Odefsey ([rilpivirine + emtricitabine + tenofovir alafenamide (TAF)]; Gilead/Johnson & Johnson) is a single-tablet regimen approved in the US and five major EU markets (France, Germany, Italy, Spain, and the UK) for the treatment of HIV-1 infection. Odefsey contains Gilead’s nucleos(t)ide reverse transcriptase inhibitors (NRTIs) TAF and Emtriva (emtricitabine), and Johnson & Johnson’s non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine; Johnson & Johnson).
Odefsey’s superior bone and renal safety profile has allowed it to cannibalize Complera’s ([rilpivirine + emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead/Johnson & Johnson) patient share, but efficacy weaknesses associated with the Edurant component limit Odefsey’s potential outside of its current positioning as a more tolerable alternative to Atripla ([efavirenz + emtricitabine + TDF]; Gilead).
4 Drug Overview
5 Product Profiles
5 Odefsey : HIV
LIST OF FIGURES
10 Figure 60: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country, 2018–27
11 Figure 61: Datamonitor Healthcare’s drug assessment summary of fostemsavir for HIV
13 Figure 62: Datamonitor Healthcare’s drug assessment summary of fostemsavir for HIV
LIST OF TABLES
6 Table 1: Odefsey drug profile
6 Table 2: Approval history of Odefsey for HIV in the US and five major EU markets
8 Table 3: Late-phase trials of Odefsey for HIV
9 Table 4: Odefsey for HIV – SWOT analysis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.